Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction

JAMA - Journal of the American Medical Association

Volumn 313, Issue 8, 2015, Pages 805-814

  Olsen, Anne Marie Schjerning ^a   Gislason, Gunnar H ^a,b   McGettigan, Patricia ^c   Fosbøl, Emil ^d   Sørensen, Rikke ^a   Hansen, Morten Lock ^a   Køber, Lars ^d   Torp Pedersen, Christian ^e   Lamberts, Morten ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Rigshospitalet   (Denmark)

^e AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CLOPIDOGREL; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; LOOP DIURETIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; SPIRONOLACTONE; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DENMARK; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; CHEMICALLY INDUCED; COMPLICATION; DRUG INTERACTION; HEMORRHAGE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK; RISK FACTORS; STROKE;

EID: 84923307510     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.0809     Document Type: Article

References (35)

1. Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93 (2):189-194.
2. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acutemyocardial infarction. Circulation. 2006;113(25):2906-2913.
3. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9): e1001098.
4. PRAC Recommends the Same Cardiovascular Precautions for Diclofenac as for Selective COX-2 Inhibitors. European Medicines Agency website. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/news-detail-001816.jsp&mid=WC0b01ac058004d5c1. June 14, 2013. Accessed January 28, 2015.
5. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642.
6. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrentmyocardial infarction in patients with priormyocardial infarction: a nationwide cohort study. Circulation. 2011;123 (20):2226-2235.
7. Olsen AM, Fosbøl EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-timemyocardial infarction: a nationwide cohort study. Circulation. 2012;126 (16):1955-1963.
8. Hart RG, Pearce LA, AguilarMI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
9. Hamm CW, Bassand JP, Agewall S, et al ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054.
10. Kushner FG, Hand M, Smith SC Jr, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of PatientsWith ST-ElevationMyocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction apears in Circulation. 2010;121(12):e257]. Circulation. 2009;120(22):2271-2306.
11. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3): 263-268.
12. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4): 445-448.
13. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012. Clin Epidemiol. 2014;6:155-168.
14. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, OslerM. The validity of the diagnosis of acutemyocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56(2):124-130.
15. Fosbøl EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6million people. Pharmacoepidemiol Drug Saf. 2008;17(8):822-833.
16. Tu JV, Austin PC,Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acutemyocardial infarction mortality prediction rules. J AmColl Cardiol. 2001;37(4):992-997.
17. Rasmussen S, Zwisler AD, Abildstrom SZ, Madsen JK, Madsen M. Hospital variation in mortality after first acutemyocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care. 2005;43(10):970-978.
18. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a priormyocardial infarction carry the same cardiovascular risk: a population study of 3.3million people. Circulation. 2008;117(15):1945-1954.
19. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients followingmyocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185-1193.
20. Cunningham A, Stein CM, Chung CP, Daugherty JR, SmalleyWE, RayWA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560-566.
21. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a national register of patients. Neuroepidemiology. 2007;28 (3):150-154.
22. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acutemyocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967-1974.
23. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
24. Bhala N, Emberson J, Merhi A, et al Coxib and Traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779.
25. Castellsague J, Riera-Guardia N, Calingaert B, et al Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-1146.
26. Lévesque LE, Brophy JM, Zhang B. Time variations in the risk ofmyocardial infarction among elderly users of COX-2 inhibitors. CMAJ. 2006;174 (11):1563-1569.
27. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633-1644.
28. Trelle S, Reichenbach S,Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
29. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med. 2010;61:17-33.
30. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, AgenoW. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381-2391.
31. Eikelboom JW,Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-2372.
32. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
33. Krishnan E, Lingala VB, Singh G. Declines in mortality from acutemyocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004;110 (13):1774-1779.
34. Sattar N,McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108(24):2957-2963.
35. Sørensen R, Abildstrom SZ,Weeke P, et al. Duration of clopidogrel treatment and risk of mortality and recurrentmyocardial infarction among 11 680 patients withmyocardial infarction treated with percutaneous coronary intervention: a cohort study. BMC Cardiovasc Disord. 2010;10:6.